The 2024 National Diabetes Care Survey, a comprehensive analysis of Type 2 diabetes patients in the U.S., highlights the growing impact of cellular remote patient monitoring (RPM)™ on diabetes management.…
BioIntelliSense, a leader in continuous health monitoring and clinical intelligence, today announced the publication of peer-reviewed research in the Journal of Clinical Medicine. The study, titled “A Retrospective Observational Study…
Exai Bio, a next-generation company specializing in oncRNA and generative AI-based liquid biopsy technologies, has announced the publication of a peer-reviewed paper in Nature Communications. The study, titled “Deep generative…
STIMIT AG announced today that it is enrolling patients in its FDA Investigational Device Exemption (IDE) clinical trial, the “STIMIT ACTIVATOR 1 PIVOTAL STUDY,” in collaboration with leading clinical centers…
DT Research, a leading provider of purpose-built computing solutions for vertical markets, and swyMed™, a top provider of telemedicine and connectivity solutions, announced that Washington County Regional Medical Center (WCRMC)…
A recent study published in Heart Rhythm highlights how artificial intelligence (AI) algorithms embedded in Medtronic’s LINQ II implantable loop recorders (ILRs) significantly reduce alert and episode burdens. This is…
Encora Therapeutics is excited to announce the successful completion of the ULTRE (Upper Limb Tremor Reduction in Essential Tremor) clinical trial. The study assessed the safety, tolerability, and effectiveness of…
SOLVD Health, a patient intelligence company focused on precision solutions to improve health outcomes, has launched a comprehensive post-approval study for AvertD®, the first FDA-approved genetic test to assess the…
At the ISPOR Europe 2024 Conference, CapeStart, Inc. unveiled MadeAi™, a generative AI-powered platform designed to revolutionize the synthesis of clinical information. The platform’s first solution, MadeAi-LR, enhances the efficiency…
Vektor Medical, a leader in non-invasive arrhythmia analysis and localization, today announced new data demonstrating the enhanced capabilities of its AI-powered solution, vMap, for improving cardiac arrhythmia treatment. The data,…
LivaNova PLC (Nasdaq: LIVN), a leading medical technology company, today announced that its OSPREY randomized controlled trial (RCT) met its primary safety and efficacy endpoints. The trial, which evaluated the…
TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology-focused company committed to improving outcomes for liver cancer patients through its advanced drug delivery technology and investigational immunotherapy nelitolimod, has entered into…